选择典型对药"都梁丸"名方，创建中药复方物质基础研究方法学。遵照中医药理论并结合现代科学技术发展，通过串联其体内过程和药代及药效动力学、研发和创新的手段等研究其有效成分及其药效组合物，制定药效组合物的化学和生物活性相关联指纹谱；以"都梁丸"为载体，探讨肝微粒体药物代谢酶亚型（如CYP3A1、3A4、1A2、2C9、2C19、2D6、2E1等）用于研究复方中药或其化学成分相互作用及与药物代谢酶亚型相互作用的技术方法，并制定相关指导原则；将国际公认、先进的模型引入到中药复方研究中，打破国际技术壁垒，从在肠内的稳定性、肠吸收转化及相互作用、体内代谢转化、分布、排泄到药效研究的系统集成上，创新中药复方的研究方法，并制定研究的指导原则，循证"都梁丸"配伍的科学性；为复方中药物质基础研究提供新的思路和方法学，为科学制定复方中药质量标准提供示范性研究模式。

Selecting a typical couplet medicine of "Duliang Pill", establish the methodology for the study of material bases of the compound traditional Chinese medicines (TCM). In compliance with the theory of TCM combined with the development of modern science and technology, study the active ingredients and their effective combination to develop the chemical ingredients - biological activity associated fingerprint of the effective combination by means of connecting the processes of metabolism and disposition in intra-body, pharmacokinetics and pharmacodynamics, as well as R & D and innovation in series; Using "Duliang Pill" as the vehicle, explore the technical methods for studying the interactions of the compound TCM or its chemical ingredients with the drug metabolism enzyme subtypes and develop the relevant guidance using the drug metabolism enzyme subtypes of liver microsome (such as CYP3A1, 3A4, 1A2, 2C9, 2C19, 2D6, 2E1, etc.); Introduce the internationally-recognized and advanced models into the study of the compound TCM, break the international technical barriers, innovate research methods of the compound TCM, develop research guidance, and probe into evidence-based scientificalness of compatibility of "Duliang Pill" from the system integration on the studies of intestinal stability, intestinal absorption and transformation as well as the interaction, in vivo metabolism and transformation, distribution, excretion and pharmacodynamics; Give new ideas and methodologies for the study of material basis of the compound TCM, and provide a exemplary model for the scientific development of the quality specification of the compound TCM.